<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01398306</url>
  </required_header>
  <id_info>
    <org_study_id>230520112</org_study_id>
    <nct_id>NCT01398306</nct_id>
  </id_info>
  <brief_title>Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours.</brief_title>
  <acronym>BANN</acronym>
  <official_title>Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to analyse the concentration dopamine and serotonin in
      thrombocytes of patients with renal cell carcinoma and neuro-endocrine tumours compared to
      the concentrations of these catecholamines in healthy volunteers. The concentration dopamine
      and serotonin in thrombocytes with and without medication will also be evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  To analyse the concentration catecholamines in thrombocytes of patients with clear cell
           renal cell carcinoma and low grade neuroendocrine tumours.

        -  To compare these concentrations with the concentrations catecholamines in thrombocytes
           of healthy controls.

        -  To analyse the concentration catecholamines in thrombocytes of patients with clear cell
           renal cell carcinoma and patients with low grade neuroendocrine tumours with and without
           medication.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in concentrations DA and 5-HT in thrombocytes of patients with clear cell renal cell carcinoma and healthy controls, and patients with low grade neuroendocrine tumours and healthy controls.</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in concentrations DA and 5-HT in thrombocytes of patients with clear cell renal cell carcinoma and low grade neuroendocrine tumours with and without medication.</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">40</enrollment>
  <condition>Carcinoma</condition>
  <condition>Carcinoma, Renal Cell</condition>
  <condition>Neuroendocrine Tumors</condition>
  <condition>Carcinoid Tumor</condition>
  <condition>Pancreatic Islet Cell Tumors</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <description>Patients with clear cell renal cell carcinoma with metastases.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <description>Patients with low grade neuro-endocrine tumours with metastases.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sampling by vena punction.</intervention_name>
    <description>We obtain 10mL blood of the patients. The blood is obtained twice: once with angiogenesis inhibitors or mTOR inhibitors, and once without.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      2 x 10mL whole blood, stored as platelet rich and platelet poor plasma.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with clear cell renal cell carcinoma with metastases and patients with low grade
        neuroendocrine tumours with metastases.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years old or older.

          -  Patients with clear cell renal cell carcinoma with metastases or patients with a
             low-grade neuro-endocrine tumor with metastases.

          -  Written informed consent

        Exclusion Criteria:

          -  Use of L-dopa or SSRI.

          -  Patients with a second primary malignancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sjoukje F. Oosting, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marloes A.M. Peters</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2011</study_first_submitted>
  <study_first_submitted_qc>July 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2011</study_first_posted>
  <last_update_submitted>May 7, 2012</last_update_submitted>
  <last_update_submitted_qc>May 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>S.F. Oosting</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Angiogenesis Inhibitors</keyword>
  <keyword>Neoplasms, Glandular and Epithelial</keyword>
  <keyword>Neoplasms by Histologic Type</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Adenocarcinoma</keyword>
  <keyword>Kidney Neoplasms</keyword>
  <keyword>Urologic Neoplasms</keyword>
  <keyword>Urogenital Neoplasms</keyword>
  <keyword>Neoplasms by Site</keyword>
  <keyword>Kidney Diseases</keyword>
  <keyword>Angiogenesis Inducing Agents</keyword>
  <keyword>Biological Markers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Carcinoid Tumor</mesh_term>
    <mesh_term>Endocrine Gland Neoplasms</mesh_term>
    <mesh_term>Adenoma, Islet Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angiogenesis Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

